248276-01-9 Usage
Explanation
The compound's name is derived from its structure, which includes a methano bridge and a benzazocine ring, along with an ethoxy group.
Explanation
The compound contains a ring structure with both carbon and other elements, making it a heterocyclic compound.
Explanation
The compound has two fused rings, which is characteristic of a bicyclic structure.
Explanation
The compound is derived from benzazocine, a tricyclic heterocyclic organic compound.
Explanation
The compound has an ethoxy (-OCH2CH3) functional group attached to it.
Explanation
The compound is considered a psychoactive drug due to its potential effects on the central nervous system.
Explanation
Research is being conducted to explore the compound's potential in treating various neurological disorders.
Explanation
The compound's structure suggests that it may interact with neurotransmitter receptors in the central nervous system, which could lead to pharmacological effects.
Explanation
Further research is being conducted to understand the compound's pharmacological properties and potential medical applications.
Type of Compound
Heterocyclic organic compound
Bicyclic Structure
Yes
Derivative of
Benzazocine
Contains
Ethoxy group
Classification
Psychoactive drug
Potential Use
Treatment of neurological disorders
Pharmacological Effects
Possible interaction with neurotransmitter receptors
Research Status
Ongoing
Check Digit Verification of cas no
The CAS Registry Mumber 248276-01-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,4,8,2,7 and 6 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 248276-01:
(8*2)+(7*4)+(6*8)+(5*2)+(4*7)+(3*6)+(2*0)+(1*1)=149
149 % 10 = 9
So 248276-01-9 is a valid CAS Registry Number.
248276-01-9Relevant academic research and scientific papers
In pursuit of α4β2 nicotinic receptor partial agonists for smoking cessation: Carbon analogs of (-)-cytisine
Coe, Jotham W.,Vetelino, Michael G.,Bashore, Crystal G.,Wirtz, Michael C.,Brooks, Paige R.,Arnold, Eric P.,Lebel, Lorraine A.,Fox, Carol B.,Sands, Steven B.,Davis, Thomas I.,Schulz, David W.,Rollema, Hans,Tingley III, F. David,O'Neill, Brian T.
, p. 2974 - 2979 (2007/10/03)
The preparation and biological activity of analogs of (-)-cytisine, an α4β2 nicotinic receptor partial agonist, are discussed. All-carbon-containing phenyl ring replacements of the pyridone ring system, generated via Heck cyclization protocols, exhibited
Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
-
, (2008/06/13)
This invention relates to the use of nicotinic acetylcholine receptor agonists for the treatment of restless legs syndrome (RLS). The invention further relates to the use of a nicotinic acetylcholine receptor agonist in the manufacture of a medicament for the treatment of RLS. The present invention also relates to a pharmaceutical composition for the treatment of RLS containing a nicotinic acetylcholine receptor agonist.
Aryl fused azapolycyclic compounds
-
, (2008/06/13)
The present invention relates to compounds of formula (I) and their pharmaceutically acceptable salts, wherein R1, R2, R3and Z are as defined herein, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders.
